Clinical Trial Update: A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial explores a tumor immune biomarker-guided strategy to improve response to Bacillus Calmette-Guérin (BCG) therapy in high-risk non-muscle inva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)

Snippet

Sponsor: Queen's University | Conditions: NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING